Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 2, 2009, Pages 303-307

  Sugino, Haruhiko ^a,b   Futamura, Takashi ^b   Mitsumoto, Yasuhide ^c   Maeda, Kenji ^b   Marunaka, Yoshinori ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

Antipsychotics; Clozapine; Cytokines; Haloperidol; Interleukin 10; Lipopolysaccharide

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ANTIGEN; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CYTOKINE; HALOPERIDOL; INTERLEUKIN 10; INTERLEUKIN 6; KETANSERIN; LIPOPOLYSACCHARIDE; OLANZAPINE; POLYINOSINIC POLYCYTIDYLIC ACID; PRAZOSIN; RISPERIDONE; SCOPOLAMINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; INFLAMMATION; MALE; MOUSE; NONHUMAN; UPREGULATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; CYTOKINES; HALOPERIDOL; INTERLEUKIN-10; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; POLY I-C; RISPERIDONE; SEROTONIN ANTAGONISTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 60049092650     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.12.006     Document Type: Article

References (46)

1. Akhondzadeh S., Tabatabaee M., Amini H., Ahmadi Abhari S.A., Abbasi S.H., and Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 90 (2007) 179-185
2. Altamura A.C., Boin F., and Maes M. HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment. Eur Neuropsychopharmacol 10 (1999) 1-4
3. Arion D., Unger T., Lewis D.A., Levitt P., and Mirnics K. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry 62 (2007) 711-721
4. Assie M.B., Dominguez H., Consul-Denjean N., and Newman-Tancredi A. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. Naunyn-Schmiedeberg's Arch Pharmacol 373 (2006) 441-450
5. Bardin L., Kleven M.S., Barret-Grevoz C., Depoortere R., and Newman-Tancredi A. Antipsychotic-like vs. cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. Neuropsychopharmacology 31 (2006) 1869-1879
6. Bian Q., Kato T., Monji A., Hashioka S., Mizoguchi Y., Horikawa H., et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-γ. Prog Neuropsychopharmacol Biol Psychiatry 32 (2008) 42-48
7. Buntinx M., Moreels M., Vandenabeele F., Lambrichts I., Raus J., Steels P., et al. Cytokine-induced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFN-γ and TNF-α on apoptosis. J Neurosci Res 76 (2004) 834-845
8. Fukuda T., Hisadome M., and Komatsu H. Treatment with Y-40138, a multiple cytokine production modulator, inhibits lipopolysaccharide- or tumour necrosis factor-α-induced production of pro-inflammatory cytokines and augments interleukin-10. J Pharm Pharmacol 57 (2005) 1461-1466
9. Futamura T., Toyooka K., Iritani S., Niizato K., Nakamura R., Tsuchiya K., et al. Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. Mol Psychiatry 7 (2002) 673-682
10. Gerard C., Bruyns C., Marchant A., Abramowicz D., Vandenabeele P., Delvaux A., et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 177 (1993) 547-550
11. Hashimoto K. Microglial activation in schizophrenia and minocycline treatment. Prog Neuropsychopharmacol Biol Psychiatry 32 (2008) 1758-1759
12. Hayley S., Brebner K., Lacosta S., Merali Z., and Anismen H. Sensitization to the effects of tumor necrosis factor-α: neuroendocrine, central monoamine, and behavioral variations. J Neurosci 19 (1999) 5654-5665
13. Hou Y., Wu C.F., Yang J.Y., He X., Bi X.L., Yu L., et al. Effects of clozapine, olanzapine and haloperidol on nitric oxide production by lipopolysaccharide-activated N9 cells. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 1523-1528
14. Howard M., Muchamuel T., Andrade S., and Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 177 (1993) 1205-1208
15. Kato T., Monji A., Hashioka S., and Kanba S. Risperidone significantly inhibits interferon-γ-induced microglial activation in vitro. Schizophr Res 92 (2007) 108-115
16. Kronfol Z., and Remick D.G. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 157 (2000) 683-694
17. Kumra S., Kranzler H., Gerbino-Rosen G., Kester H.M., DeThomas C., Kafantaris V., et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 63 (2008) 524-529
18. Leykin I., Mayer R., and Shinitzky M. Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology 37 (1997) 75-86
19. Lin A., Kenis G., Bignotti S., Tura G.J., De Jong R., Bosmans E., et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 32 (1998) 9-15
20. Maes M., Meltzer H.Y., and Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 89 (1994) 346-351
21. Maes M., Bosmans E., Calabrese J., Smith R., and Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 29 (1995) 141-152
22. Maes M., Bosmans E., Kenis G., De Jong R., Smith R.S., and Meltzer H.Y. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 26 (1997) 221-225
23. Maes M., Bocchio L., Bignotti S., Tura G.B., Pioli R., Boin F., et al. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 10 (2000) 119-124
24. Maes M., Bocchio L., Bignotti S., Tura G.B., Pioli R., Boin F., et al. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 54 (2002) 281-291
25. Marchant A., Bruyns C., Vandenabeele P., Ducarme M., Gerard C., Delvaux A., et al. Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 24 (1994) 1167-1171
26. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163 (2006) 600-610
27. Monteleone P., Fabrazzo M., Tortorella A., and Maj M. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Research 71 (1997) 11-17
28. Muller N., and Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 22 (1998) 1-33
29. Muller N., and Schwarz M.J. COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des 14 (2008) 1452-1465
30. Muller N., and Schwarz M.J. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur Arch Psychiatry Clin Neurosci 258 Suppl 2 (2008) 97-106
31. Muller N., Hofschuster E., Ackenheil M., and Eckstein R. T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy. Acta Psychiatr Scand 87 (1993) 66-71
32. Muller N., Empl M., Riedel M., Schwarz M., and Ackenheil M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci 247 (1997) 308-313
33. Muller N., Riedel M., Ackenheil M., and Schwarz M.J. The role of immune function in schizophrenia: an overview. Eur Arch Psychiatry Clin Neurosci 249 Suppl 4 (1999) 62-68
34. Muller N., Ulmschneider M., Scheppach C., Schwarz M.J., Ackenheil M., Moller H.J., et al. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci 254 (2004) 14-22
35. Nawa H., and Takei N. Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neurosci Res 56 (2006) 2-13
36. O'Brien S.M., Scully P., and Dinan T.G. Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Research 160 (2008) 256-262
37. Ozawa K., Hashimoto K., Kishimoto T., Shimizu E., Ishikura H., and Iyo M. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry 59 (2006) 546-554
38. Pollmacher T., Hinze-Selch D., and Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 16 (1996) 403-409
39. Pollmacher T., Hinze-Selch D., Fenzel T., Kraus T., Schuld A., and Mullington J. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Am J Psychiatry 154 (1997) 1763-1765
40. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., and Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63 (2008) 801-808
41. Robertson S.A., Skinner R.J., and Care A.S. Essential role for IL-10 in resistance to lipopolysaccharide-induced preterm labor in mice. J Immunol 177 (2006) 4888-4896
42. Saetre P., Emilsson L., Axelsson E., Kreuger J., Lindholm E., and Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 7 (2007) 46
43. Song C., Lin A., Kenis G., Bosmans E., and Maes M. Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr Res 42 (2000) 157-164
44. Strous R.D., and Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun 27 (2006) 71-80
45. Teixeira A.L., Reis H.J., Nicolato R., Brito-Melo G., Correa H., Teixeira M.M., et al. Increased serum levels of CCL11/eotaxin in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32 (2008) 710-714
46. Zalcman S., Murray L., Dyck D.G., Greenberg A.H., and Nance D.M. Interleukin-2 and -6 induce behavioral-activating effects in mice. Brain Res 811 (1998) 111-121